Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma.
Luginbuhl AJ, Johnson JM, Harshyne LA, Linnenbach AJ, Shukla SK, Alnemri A, Kumar G, Cognetti DM, Curry JM, Kotlov N, Antysheva Z, Degryse S, Mannion K, Gibson MK, Netterville J, Brown B, Axelrod R, Zinner R, Tuluc M, Gargano S, Leiby BE, Shimada A, Mahoney MG, Martinez-Outschoorn U, Rodeck U, Kim YJ, South AP, Argiris A.
Luginbuhl AJ, et al. Among authors: kim yj.
Clin Cancer Res. 2022 Mar 1;28(5):915-927. doi: 10.1158/1078-0432.CCR-21-1816.
Clin Cancer Res. 2022.
PMID: 34911681
Free PMC article.
Clinical Trial.